Edition:
United Kingdom

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.80USD
4:25pm BST
Change (% chg)

$0.02 (+1.12%)
Prev Close
$1.78
Open
$1.79
Day's High
$1.80
Day's Low
$1.77
Volume
2,455
Avg. Vol
66,173
52-wk High
$6.70
52-wk Low
$1.09

Latest Key Developments (Source: Significant Developments)

Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Heat Biologics Inc ::SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL.HEAT BIOLOGICS - RECEIVED WRITTEN RESPONSES FROM U.S. FDA REGARDING HS-110 TRIAL DESIGN FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.HEAT BIOLOGICS - FDA AGREED THAT TRIAL DESIGNS, BOTH SINGLE-ARM AND CONTROLLED, WOULD BE APPROPRIATE TO SUPPORT REGISTRATIONAL TRIAL OF HS-110.HEAT BIOLOGICS - TRIAL DESIGN DETAILS AND NEXT STEPS EXPECTED TO BE ANNOUNCED FOLLOWING READ-OUT OF PHASE 2 DATA, ANTICIPATED IN 2H 2018.  Full Article

Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Heat Biologics Inc :Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​.Heat Biologics Inc - ‍cash and cash equivalents totaled approximately $4.3 million, as of September 30, 2017​.  Full Article

Heat Biologics Inc files for mixed shelf of up to $50 million ‍​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Heat Biologics Inc :Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​.  Full Article